Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense

This article was originally published in The Pink Sheet Daily

Executive Summary

Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.

You may also be interested in...



Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007

Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.

Related Content

Topics

UsernamePublicRestriction

Register

PS063652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel